Prostate Cancer Treatment and Research

This study develops a ddPCR method to detect low-abundance TMPRSS2:ERG gene fusion transcripts in prostate cancer cells and evaluates potential initiators of these fusions.

The paper shows TRIM33 enhances AR activity by reducing H2BK120 ubiquitination, without affecting AR protein stability.

This study identifies granulin+ macrophages as drivers of lineage plasticity in prostate cancer through paracrine signaling loops, promoting drug resistance.

The paper identifies a gene and protein expression signature associated with HOXB13 G84E carrier status in prostate cancer using proteogenomic analysis.

This study shows that combining Celastrol and bicalutamide enhances cytotoxicity, apoptosis, and immunogenic cell death in castration-resistant prostate cancer.

This study identifies DPYSL3B as a regulator of chemoresistance in prostate cancer by enhancing DNA repair and metabolic reprogramming, with implications for therapeutic targeting.

The paper identifies genomic alterations in the YAP/TAZ pathway associated with stem cell-like castration-resistant prostate cancer using transcriptomic and whole-genome sequencing data.

This study compares 3D culture scaffolds for prostate cancer cells, finding scaffold-dependent differences in spheroid formation and gene expression, particularly in neuroendocrine markers.

This study identifies BET inhibitors as effective against GI transcriptome-positive CRPC by targeting HNF1A and HNF4G, improving outcomes in preclinical models.

This paper identifies a covalent compound EN1441 that selectively degrades AR and AR-V7 in androgen-independent prostate cancer cells by targeting an intrinsically disordered cysteine.

This study characterizes the transcriptome of metastatic hormone-naive prostate cancer, identifying stroma remodelling and SOX11's role in metastasis.

This study characterizes transcriptomic and phenotypic changes in prostate cancer cells developing resistance to bicalutamide and enzalutamide, showing treatment sequence affects drug resistance and docetaxel sensitivity.

This study identifies OGDHL as a regulator of tumor growth, neuroendocrine marker expression, and nucleotide abundance in prostate cancer, with implications for treatment resistance.

This study identifies Notch signaling as a driver of lineage plasticity and therapeutic resistance in enzalutamide-resistant prostate cancer and shows its inhibition reverses resistance in vitro.

This study uses longitudinal single-cell RNA sequencing to identify RUNX1T1 as a key regulator in the transition and maintenance of treatment-induced neuroendocrine prostate cancer.

This study shows that EZH2 influences the evolution of aggressive prostate cancer subtypes but is not essential for neuroendocrine prostate cancer development.

This study identifies a RIPK2-regulated gene signature that correlates with prognosis in prostate cancer and responds to RIPK2 inhibitors.

This study identifies Neurog2 as a potential therapeutic target for MYCN-driven neuroendocrine prostate cancer by showing its role in promoting tumor growth and NEPC development.

This study identifies rare germline variants associated with metastatic prostate cancer using an extreme phenotype cohort and validates their functional impact.

The paper uses machine learning to identify distinct biological processes and druggable targets in early-onset prostate cancer compared to late-onset prostate cancer.

This study identifies spermidine synthase as a PGC1-regulated secreted protein that mediates paracrine tumor suppression in prostate cancer, highlighting a non-cell autonomous mechanism.

This study identifies a bacterial pathway for androgen production, showing that gut and urinary bacteria can convert androstenedione to epitestosterone and testosterone, which promote prostate cancer growth.

This study identifies a hypoxic eIF1A+ luminal cell cluster in prostate cancer that promotes tumor progression and creates an immunosuppressive microenvironment, with potential therapeutic implications.

This study uses single-cell RNA-sequencing to identify a therapy-resistant subpopulation in prostate cancer cells and discovers a potential therapeutic target for enzalutamide resistance.

This study shows that oncogenic signaling in adult Drosophila accessory glands activates a pro-tumorigenic program without proliferation, leading to tissue hyperplasia and aneuploidy through endoreduplication.

This study shows that voluntary exercise reduces tumor growth in a mouse model of castration-resistant prostate cancer by affecting DNA replication, AR signaling, and mitochondrial dynamics.

This study identifies TET2 activation in slow-cycling cells as a driver of prostate cancer progression through epigenetic changes and shows targeting TET2 suppresses tumor growth.

This study identifies MMP11 as a blood-based biomarker for prostate cancer progression, regulated by the ALDH1A1-TGF-β1 signaling pathway.

The paper shows that loss of canonical sex steroid signaling in Drosophila prostate cancer models correlates with tumor progression and induces tumor escape by altering epithelial basal extrusion.

This study identifies lineage-specific transcription factor profiles in prostate cancer progression, revealing dynamic shifts during NE transdifferentiation and proposing a three-phase model.